Click here to sign in with or
Forget Password?
Learn more
share this!
1
3
Share
Email
December 20, 2022
by National University of Ireland, Galway
University of Galway, in collaboration with the NEPHSTROM Consortium, has announced promising results from a new cell therapy trial for people living with diabetes.
The NEPHSTROM clinical trial is taking the first steps to investigate the value of a novel cell therapy for adults who have type 2 diabetes and worsening kidney disease, despite best medical treatment.
Results from the NEPHSTROM clinical trial were presented in November at the American Society of Nephrology’s Kidney Week meeting in Orlando, Florida. It showed that a single dose of ORBCEL-M, given intravenously to carefully selected adults with worsening kidney disease due to diabetes was safe and associated with better preservation of kidney function compared to a placebo. Patients taking part in the trial were followed closely for 18 months after receiving ORBCEL-M.
The ORBCEL-M cell therapy is a mesenchymal stromal cell (MSC) preparation manufactured from healthy bone marrow which was discovered and developed in Galway by Orbsen Therapeutics Ltd, a spinout company from University of Galway.
The clinical trial is being led from the Mario Negri Institute for Pharmacological Research IRCCS in Bergamo, Italy and carried out jointly at leading medical centers in Galway, Bergamo, Birmingham and Belfast.
Trial investigator, Professor Matt Griffin, a senior researcher at University of Galway’s Regenerative Medicine Institute (REMEDI) and a Consultant Nephrologist at Galway University Hospitals said, “Nearly a quarter of a million people in Ireland are living with diabetes and we know that more than 40% of them have evidence of kidney disease—often referred to as diabetic kidney disease or DKD for short.
“In type 2 diabetes, as many as one third of those with DKD have worsening kidney function despite the best medical therapy we can offer. These people are at high risk for requiring dialysis or kidney transplantation in the years ahead—both of which are complex treatments with potentially serious complications.”
“In NEPHSTROM, our goal is to secure evidence that a cell therapy, such as ORBCEL-M, is safe and can slow the course of DKD to help more people with diabetes avoid the need for dialysis or transplantation. It was exciting to report that our first analysis of results from the trial supports that goal.”
Dr. Steve Elliman, who discovered the ORBCEL-M therapy, is Chief Scientific Officer for Orbsen Therapeutics. Dr. Elliman said, “At Orbsen Therapeutics we are motivated by improving patient care. Diabetic patients with progressive kidney disease eventually require dialysis and often a kidney transplant. While dialysis improves the quality of life of patients with kidney failure, it is expensive and does not prevent further decline of kidney function.”
“Additionally, dialysis takes four hours per session and three times a week—creating logistic and economic challenges for the patient. Our goal with ORBCEL-M is to resolve systemic inflammation and improve kidney function, so that patients will not require dialysis or a kidney transplant. We’re encouraged by the safety profile and the preliminary efficacy signals in patients with DKD reported by the NEPHSTROM trial. We look forward to continued collaboration with our University of Galway and NEPHSTROM partners to advance this new medicine through Phase 3 efficacy trials and a market approval.”
Dr. Veronica McInerney, Administrative Director at the HRB Clinical Research Facility at University of Galway said, “Without patient involvement in clinical trials, advances in new treatments are simply not possible. We are fortunate to have the HRB Clinical Research Facility Galway, a clinically equipped space to see and treat patients on trials. We are hopeful that future generations will benefit from the willingness of patients to participate in trials, such as the NEPHSTROM trial.”
Professor Timothy O’Brien, Director of the Regenerative Medicine Institute (REMEDI), at the University of Galway and Consultant Physician in Endocrinology at Galway University Hospitals and the overall lead of the NEPHSTROM project, said, “University of Galway’s ecosystem is set up to facilitate and lead international trials of this nature. The Cell Therapy GMP manufacturing facilities at the Centre for Cell Manufacturing Ireland, located in the University, along with the HRB Clinical Research Facility, the close partnership with Saolta University Heath Care Group and REMEDI have been instrumental in making the progression of this potential new therapy possible.”
Explore further
Facebook
Twitter
Email
Feedback to editors
12 hours ago
1
Dec 20, 2022
0
Dec 20, 2022
0
Dec 19, 2022
1
Dec 19, 2022
0
3 hours ago
4 hours ago
4 hours ago
4 hours ago
6 hours ago
6 hours ago
6 hours ago
6 hours ago
7 hours ago
7 hours ago
Jun 14, 2021
Nov 6, 2021
Nov 7, 2022
Dec 18, 2021
Dec 28, 2021
Nov 5, 2017
4 hours ago
6 hours ago
3 hours ago
12 hours ago
11 hours ago
10 hours ago
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.